At a glance
ClinicalIndex Comparison Record- ✓Advanced cancer expressing Mesothelin protein
- ✓Life expectancy greater than 12 weeks
- ✓Adequate heart, lung, liver, kidney, and blood function
- ✓Autologous transduced T cells with ≥20% Mesothelin-CAR expression by flow-cytometry
- ✕Prior gene therapy
- ✕Severe viral infection (HBV, HCV, HIV, etc.)
- ✕Known HIV positivity
- ✕Active infectious disease (bacterial, viral, fungal)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mesothelin/GPC3/GUCY2C Targeted CAR-T for Immunotherapy of Pancreatic Cancer: Phase I Clinical Trial
In Brief
A Phase 1 clinical trial evaluating CAR-T cells for Pancreas Cancer and 3 related conditions. Currently recruiting, targeting 30 participants across 1 site.
Detailed Summary
The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.
Study Details
Timeline
Interventions
Transfer CAR-T cells into patients for anti-ancer therapy.